

CONSENSUS STATEMENT OPEN



Adult hypertension referral pathway and therapeutic management: British and Irish Hypertension Society position statement

Philip Lewis¹, Jacob George², Vikas Kapil³, Neil R. Poulter⁴, Sarah Partridge⁵✉, James Goodman⁶, Luca Faconti⁷, Terry McCormack⁸ and Ian B. Wilkinson⁹

© The Author(s) 2024

In the UK, most adults with hypertension are managed in Primary Care. Referrals to Secondary Care Hypertension Specialists are targeted to patients in whom further investigations are likely to change management decisions. In this position statement the British and Irish Hypertension Society provide clinicians with a framework for referring patients to Hypertension Specialists. Additional therapeutic advice is provided to optimise patient management whilst awaiting specialist review. Our aim is to ensure that referral criteria to Hypertension Specialists are consistent across the UK and Ireland to ensure equitable access for all patients.

Journal of Human Hypertension (2024) 38:3–7; <https://doi.org/10.1038/s41371-023-00882-2>

INTRODUCTION

In the UK, most adults with hypertension are managed in Primary Care. National and international guidelines advise that adult referrals to Secondary Care Hypertension Specialists are targeted at patients in whom further investigations are likely to change management decisions [1–6]. Referrals are recommended when patients have raised blood pressure with life threatening target-organ damage (i.e. emergency/same day referrals); or when patients have, for example, suspected secondary hypertension, resistant hypertension, or complex polypharmacy (i.e. routine referrals) [1–6].

In this statement, the British and Irish Hypertension Society (BIHS) summarise their recommendations for adult emergency and routine referrals to Secondary Care Hypertension Specialists and highlight where this advice is supported by the National Institute for Health and Care Excellence (NICE) and/or International Societies (Tables 1 and 2) [1–6]. Table 3 summarises the ideal information to accompany referrals to facilitate communication between Primary and Secondary Care services. Where there are long waiting times to access routine Secondary Care hypertension services, the BIHS offer additional therapeutic advice to optimise patient management whilst awaiting specialist review (Fig. 1). Finally, the challenges facing referrers in identifying a Hypertension Specialist in the UK are discussed.

ADULT REFERRAL CRITERIA TO A SECONDARY CARE HYPERTENSION SPECIALIST

The clinical situations where the BIHS recommends emergency/same day referrals are outlined in Table 1.

The clinical situations where the BIHS recommends routine referrals are outlined in Table 2.

Prior to making routine referrals, clinicians should have:

1. Confirmed hypertension is present by either Ambulatory Blood Pressure Monitoring (ABPM) or Home Blood Pressure Monitoring (HBPM).
AND if applicable,
2. Followed NICE guidelines NG136 on hypertension management [1], Fig. 1.
3. Assessed concordance with medication (preferably by urine testing, where available [7]).

INFORMATION TO SHARE WITH HYPERTENSION SPECIALISTS

To facilitate communication between referrers and Hypertension Specialists, the BIHS recommends that, where possible, the information in Table 3 is included with the referral. This avoids patients undergoing repeated testing unnecessarily, maximises the efficient use of resources and enables patients to start new, or modified, treatment regimens as soon as possible.

¹Stockport NHS Foundation Trust, Stockport SK2 7JE, UK. ²Division of Molecular & Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK. ³William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, Queen Mary University London, London EC1M 6BQ, UK. ⁴Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London W12 7RH, UK. ⁵Department of Primary Care and Public Health, Brighton and Sussex Medical School, University of Sussex, Brighton BN1 9PH, UK. ⁶Department of Clinical Pharmacology and Therapeutics, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. ⁷King's College London British Heart Foundation Centre, Department of Clinical Pharmacology, 4th Floor, North Wing, St. Thomas' Hospital, Westminster Bridge, London SE17EH, UK. ⁸Institute of Clinical and Applied Health Research, Hull York Medical School, Hull HU6 7RX, UK. ⁹Division of Experimental Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK. ✉email: s.partridge@bsms.ac.uk

Received: 13 November 2023 Revised: 23 November 2023 Accepted: 30 November 2023

Published online: 9 January 2024

MANAGEMENT ADVICE FOR ROUTINE REFERRALS AWAITING HYPERTENSION SPECIALIST REVIEW

The BIHS acknowledges that current waiting times for routine NHS referrals may be considerable. To optimise hypertension treatment whilst patients await specialist review, clinicians may wish to consider the following steps:

- For newly diagnosed patients in whom secondary causes are suspected, or aged <40 years at diagnosis, or post-partum, a non renin-angiotensin-aldosterone system interfering drug is preferred (e.g. amlodipine or equivalent) as a temporary treatment while awaiting specialist review. This will facilitate interpretation of screening tests for the secondary causes of hypertension. Definitive long-term therapy should follow the guidance in Fig. 1.
- For those with established and uncontrolled hypertension, having tried multiple drug therapies, additional therapeutic options are summarised in Fig. 1. The choice of exemplar

drugs within each class was based on the totality of evidence for each drug in reducing morbidity and mortality combined with duration of action. Long acting drugs are strongly preferred to minimise the impact of a missed dose and reduce blood pressure variability.

- Clinicians may also find patients are willing to revisit lifestyle modifications, including optimising weight, salt and alcohol intake and review their medication concordance whilst awaiting specialist advice. Re-assessing white coat hypertension by ABPM or HBPM can also be helpful [8].

SELECTION OF A HYPERTENSION SPECIALIST

It is important to refer patients to Hypertension Specialists who have appropriate training, experience and interest in hypertension management and who have access to specialist facilities to conduct relevant investigations. In the UK, there is currently no

Table 1. BIHS criteria for emergency/same day referrals.

Clinical Situation	Supported by
Malignant/accelerated phase hypertension. Blood pressure $\geq 180/120$ mmHg with retinal haemorrhages or papilloedema	NICE [1], ESC/ESH [4, 5]
Hypertensive crisis. Life threatening target-organ damage even in the context of mild or severe hypertension, including, but not limited to, acute aortic dissection, acute kidney injury, acute myocardial ischaemia, acute heart failure, acute stroke or phaeochromocytoma.	NICE [1], ESC/ESH [4, 5]
Pre-eclampsia and severe hypertension in pregnancy. Requires a multi-disciplinary team approach.	NICE [1, 3], ESC/ESH [4, 5]

NICE National Institute for Health and Care Excellence, ESC European Society of Cardiology, ESH European Society of Hypertension.

Table 2. BIHS criteria for routine referrals.


Clinical situation	Supported by
Aged under 40 years at diagnosis, irrespective of current age	NICE [1], ESC/ESH [4, 5]
Suspected secondary hypertension, including, but not limited to hyperaldosteronism (e.g. hypokalaemia); phaeochromocytoma (e.g. palpitations, headache, flushing, family history, history of neurofibromatosis); drug-induced hypertension (e.g. concomitant prescription of combined oral contraceptive pill or implant, hormone substitutes, steroids, NSAIDs, VEGF inhibitors, tyrosine kinase inhibitors (TKIs), tricyclic antidepressants, SSNRIs, dexamphetamine, methylphenidate). <i>Please note these are common examples but do not represent an exhaustive list of the secondary causes of hypertension.</i>	NICE [1], ESC/ESH [4, 5], ISH [6]
Hypertension in pregnancy (requires a multi-disciplinary team approach) AND women who remain hypertensive postpartum.	NICE [1, 3]
Resistant hypertension, defined as blood pressure uncontrolled on maximum tolerated doses of angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor antagonist/blocker (ARB) + dihydropyridine calcium channel blocker (CCB) + thiazide-like diuretic (see Fig. 1).	NICE [1], ESC/ESH [4, 5], ISH [6]
Persistent symptomatic postural hypotension, despite medication adjustment (supine to standing after at least 1 minute, SBP falls by ≥ 20 mmHg and/or DBP falls by ≥ 10 mmHg).	NICE [1, 2]
Complex polypharmacy	ESC/ESH [4, 5]

ESC European Society of Cardiology, ESH European Society of Hypertension, ISH International Society of Hypertension, NICE National Institute for Health and Care Excellence, NSAIDs Nonsteroidal Anti-inflammatory Drugs, SSNRI selective serotonin noradrenaline reuptake inhibitor, VEGF vascular endothelial growth factor.

Table 3. Information to share with hypertension specialists.

History	Investigations (where possible)
<ul style="list-style-type: none"> • Reason for referral • Current medication • Previous intolerance to specific antihypertensive drugs with reasons • Relevant medical history and family history • Duration of hypertension / age at diagnosis 	<ul style="list-style-type: none"> • Blood and urine test results • Ambulatory and/or home blood pressure monitoring results • ECG and/or echocardiography results • Imaging reports (e.g. CXR, renal ultrasound, CT or MRI)

ECG electrocardiogram, CXR chest x-ray, CT computed tomography, MRI magnetic resonance imaging.



specialist registration for hypertension doctors and the only medical training curriculum that includes a specific module in hypertension is Clinical Pharmacology and Therapeutics. The BIHS is currently working on a system for accreditation and recognition of specialist hypertension services in the UK. In the interim, referrers can check if their local Hypertension Specialist is

a member of the British and Irish Hypertension Society (Email: bihs@in-conference.org.uk), holds a European Hypertension Specialist certificate (<https://www.eshonline.org/communities/hypertension-specialist/directory-of-specialists/>) or works at a European Hypertension Centre of Excellence (<https://www.eshonline.org/communities/excellence-centres/>).

Fig. 1 BIHS adult hypertension pathway therapeutic management. ABPM ambulatory blood pressure monitoring, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker, eGFR estimated glomerular filtration rate, HBPM home blood pressure monitoring, SPC single pill combination. *The availability of SPCs is currently limited in the UK and the only triple-component combination contains amlodipine, hydrochlorothiazide and olmesartan. Hydrochlorothiazide has been linked with an increased risk of skin cancer [9] and MHRA recommendations should be followed [10]. **a** Consider a trial of lifestyle optimisation for 3 months if BP is borderline elevated, especially where there are modifiable lifestyle risk factors including obesity, excess salt or excess alcohol intake. **b** Check for postural hypotension in those with frailty, aged >80 years, multi-morbidity, type 2 diabetes mellitus, Parkinson's disease, or symptoms. In individuals with postural hypotension treat to a standing BP target. **c** See Table 2 for the criteria for routine referrals to a Hypertension Specialist. **d** See Table 1 for the criteria for emergency/same day referrals to a Hypertension Specialist. **e** Consider pre-payment certificates, dosette boxes, alarms or electronic reminders. **f** Encourage lifestyle modifications, including optimising body weight, salt and alcohol intake. Promote smoking cessation to reduce total cardiovascular risk. Re-review other drugs/supplements including: concomitant prescription of combined oral contraceptive pill or implant, hormone substitutes, steroids, NSAIDs, VEGF inhibitors, tyrosine kinase inhibitors (TKIs), tricyclic antidepressants, SSNRIs, dexamphetamine, methylphenidate, herbal supplements, illicit substances and liquorice. Consider co-existing medical conditions (e.g. sleep apnoea, aortic coarctation, chronic kidney disease). **g** To be avoided in patients with hyperkalaemia or at increased risk of developing hyperkalaemia. May be useful if hypokalaemia or heart failure. Can titrate to 25 or 50 mg. Check electrolytes and creatinine at each titration and ensure potassium remains <5.5 mmol/l (or upper limit of normality according to local laboratories). If feminising effect e.g. gynaecomastia, change to eplerenone at twice the dose, or amiloride. **h** May cause postural hypotension especially in the frail and older persons (ideally avoid), and in those with multiple co-morbidities. May cause stress incontinence in ~15% women. If a male is on another alpha blocker, e.g. Tamsulosin, then stop and use doxazosin for both hypertension and bladder outflow benefit. Doxazosin XL 4 mg OD or Doxazosin XL 8 mg OD have a smoother pharmacokinetic profile and reduce the incidence of postural hypotension. **i** Recommended in ischaemic heart disease. Avoid in asthma. May help with anxiety, although propranolol is likely to be more effective. **j** Consider halving the starting dose in those with heart failure (e.g. lisinopril 5 mg OD). Consider candesartan for dual BP control and migraine prophylaxis.

REFERENCES

- National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2022. Accessed 23/10/2023. <https://www.nice.org.uk/guidance/ng136>
- National Institute for Health and Care Excellence. Surveillance Report: 2023 surveillance of hypertension in adults: diagnosis and management (NICE guideline NG136) and transient loss of consciousness ('blackouts') in over 16s (NICE guideline CG109). Updated Feb 2023. Accessed 23/10/2023. <https://www.nice.org.uk/guidance/ng136/evidence>
- National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. 2019. Accessed 23/10/2023. <https://www.nice.org.uk/guidance/ng133>
- Williams B, Mancia G, Spiering W, Agabiti-Rosei E, Azizi M, Burnier M, et al. Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J*. 2018;38:3021–104. <https://doi.org/10.1093/eurheartj/ehy339>
- Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*. 2023;41:1874–2071. <https://doi.org/10.1097/HJH.0000000000003480>
- Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75:1334–57. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15026>
- Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. *Heart*. 2014;100:855–61. <https://doi.org/10.1136/heartjnl-2013-305063>
- McCormack T, Cappuccio F. 10 steps before you refer for: hypertension. *Br J Cardiol*. 2008;15:254–57. <https://bjcardio.co.uk/2008/09/10-steps-before-you-refer-for-hypertension/>
- Faconti L, Ferro A, Webb AJ, Cruickshank JK, Chowieńczyk PJ on behalf of the British and Irish Hypertension Society. Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. *J Hum Hypertens*. 2019;33:257–58. <https://doi.org/10.1038/s41371-019-0190-2>
- Medicines and Healthcare products Regulatory Agency. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use. Published 14 November 2018. Accessed 23/10/2023. <https://www.gov.uk/drug-safety-update/hydrochlorothiazide-risk-of-non-melanoma-skin-cancer-particularly-in-long-term-use>

ACKNOWLEDGEMENTS

We would like to thank the following members of the BIHS Guideline Standing Committee for their expert review of this manuscript: Professor Adrian J.B. Brady, Dr Andrew Jordan, Dr

Spoorthy Kulkarni, Professor Peter Sever and Dr Wayne Sunman. We also thank the BIHS Executive Committee for their expert review and approval of the final draft of the manuscript: Professor Philip Chowieńczyk, Dr Pankaj Gupta, Dr Sinéad McDonagh, Mr Sam Olden, Dr James Sheppard and Dr Pauline Swift. We confirm that all authors were excluded from the BIHS Peer Review and Approval process.

AUTHOR CONTRIBUTIONS

PL, JG, VK, SP and IBW wrote the initial draft. PL proposed the first version of Fig. 1 that was subsequently developed by JG, IBW and NRP. All authors critically appraised the manuscript while providing expert input and contributing to the formulation of position statements and therapeutic advice. All authors reviewed the final draft.

COMPETING INTERESTS

Professor Adrian J.B. Brady has received honoraria from Daiichi-Sankyo, Amgen, Sanofi-Aventis, Bayer, MSD, and Novartis. Professor Phil Chowieńczyk has an interest in Centron Diagnostics, a company that has produced technology for blood pressure measurement. Professor Jacob George has received consultation fees as a member of the scientific advisory board of Novartis and funding for conference attendances from Daiichi-Sankyo. Dr Pankaj Gupta has received research grants, lecture honoraria and funding for conference attendance from Sanofi-Aventis and Amgen, and consulting fees from Ionis Pharmaceuticals. Professor Terry McCormack has received lecture honoraria and/or consultation fees from Amarin, AstraZeneca, Bayer, Daiichi-Sankyo, Medtronic, Novartis, OMRON and Sanofi-Aventis. Dr Sinéad McDonagh is currently funded by an NIHR School for Primary Care Research Postdoctoral Fellowship. Professor Neil R Poulter has received lecture honoraria and/or consultation fees from several pharmaceutical companies that manufacture blood pressure lowering agents including AstraZeneca, Eva Pharma, Lri Therapharma, Napi, Pfizer, Servier and Sanofi-Aventis. Dr Pauline Swift has received lecture honoraria from Astra-Zenica, Boehringer-Ingelheim and Bayer. Professor Ian B Wilkinson has received research grants from AstraZeneca, GSK and scientific advisory board consultation fees for Viatrix. LF, JG, AJ, VK, SK, PL, PS, JS, WS, SO, and SP have no competing interest to declare for this manuscript.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Sarah Partridge.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024